Biomagnetics Diagnostics Corp., (PINK SHEETS:BMGP - News) a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis, cholera and malaria detection, and other innovative technologies, announced the identification of a second biomarker for development of a tuberculosis assay. This is a significant milestone in the cooperative research agreement that was signed between Los Alamos National Laboratory and Biomagnetics, representing a major step in the development of a new point-of-care diagnostic system. In parallel, development of assays for two different tuberculosis biomarkers and the Cholera toxin is currently in progress. In addition to the first tuberculosis biomarker, assay development for a second biomarker has also commenced.

Clayton Hardman, CEO of Biomagnetics commented, "The hand-held version of the Integrated Optical Biosensor ("IOBS"), being developed by BioMagnetics, is specifically designed to be field deployable and ultraportable, allowing for the rapid detection of various pathogens by relatively untrained personnel outside the laboratory setting, at a lower cost than traditional diagnostic technologies. We believe these devices hold the potential to revolutionize disease detection, saving millions of lives in the process. We are clearly honored to be working with the very prestigious and highly qualified scientific staff at Los Alamos National Laboratory."

Source:
Biomagnetics Diagnostics Corp.